Cargando…

Effects of H(2)O(2) Treatment Combined With PI3K Inhibitor and MEK Inhibitor in AGS Cells: Oxidative Stress Outcomes in a Model of Gastric Cancer

Gastric cancer is worldwide the fifth and third cancer for incidence and mortality, respectively. Stomach wall is daily exposed to oxidative stress and BER system has a key role in the defense from oxidation-induced DNA damage, whilst ErbB receptors have important roles in the pathogenesis of cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Savino, Luca, Di Marcantonio, Maria Carmela, Moscatello, Carmelo, Cotellese, Roberto, Centurione, Lucia, Muraro, Raffaella, Aceto, Gitana Maria, Mincione, Gabriella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966616/ https://www.ncbi.nlm.nih.gov/pubmed/35372019 http://dx.doi.org/10.3389/fonc.2022.860760

Ejemplares similares

Emerging Role of Oxidative Stress on EGFR and OGG1-BER Cross-Regulation: Implications in Thyroid Physiopathology
por: Moscatello, Carmelo, et al.
Publicado: (2022)

Oxidative Distress Induces Wnt/β-Catenin Pathway Modulation in Colorectal Cancer Cells: Perspectives on APC Retained Functions
por: Catalano, Teresa, et al.
Publicado: (2021)

Eradication of Helicobacter pylori and Gastric Cancer: A Controversial Relationship
por: Piscione, Mariagrazia, et al.
Publicado: (2021)

PDAC, the Influencer Cancer: Cross-Talk with Tumor Microenvironment and Connected Potential Therapy Strategies
por: Mercanti, Leonardo, et al.
Publicado: (2023)

A Narrative Review on Non-Cirrohotic Portal Hypertension: Not All Portal Hypertensions Mean Cirrhosis
por: Fiordaliso, Michele, et al.
Publicado: (2023)

Targeting Wnt/β-Catenin Pathways in Primary Liver Tumours: From Microenvironment Signaling to Therapeutic Agents
por: Selvaggi, Federico, et al.
Publicado: (2022)

Synthesis and Biological Evaluation of Carvacrol-Based Derivatives as Dual Inhibitors of H. pylori Strains and AGS Cell Proliferation
por: Sisto, Francesca, et al.
Publicado: (2020)

Doxorubicin-induced oxidative and nitrosative stress: Mitochondrial connexin 43 is at the crossroads
por: Pecoraro, Michela, et al.
Publicado: (2020)

Synthesis and Evaluation of Thymol-Based Synthetic Derivatives as Dual-Action Inhibitors against Different Strains of H. pylori and AGS Cell Line
por: Sisto, Francesca, et al.
Publicado: (2021)

Identification of the zinc finger 216 (ZNF216) in human carcinoma cells: a potential regulator of EGFR activity
por: Mincione, Gabriella, et al.
Publicado: (2016)

Wingless/It/β-catenin signaling in liver metastasis from colorectal cancer: A focus on biological mechanisms and therapeutic opportunities
por: Selvaggi, Federico, et al.
Publicado: (2023)

Infectious Agents Induce Wnt/β-Catenin Pathway Deregulation in Primary Liver Cancers
por: Catalano, Teresa, et al.
Publicado: (2023)

Antimicrobial and Antibiofilm Activities of New Synthesized Silver Ultra-NanoClusters (SUNCs) Against Helicobacter pylori
por: Grande, Rossella, et al.
Publicado: (2020)

Germline TP53 mutation spectrum in Sudanese premenopausal breast cancer patients: correlations with reproductive factors
por: Aceto, Gitana Maria, et al.
Publicado: (2019)

Perineural Invasion in Pancreatic Ductal Adenocarcinoma: From Molecules towards Drugs of Clinical Relevance
por: Selvaggi, Federico, et al.
Publicado: (2022)

Relationship between MUTYH, OGG1 and BRCA1 mutations and mRNA expression in breast and ovarian cancer predisposition
por: Moscatello, Carmelo, et al.
Publicado: (2021)

Detection and Physicochemical Characterization of Membrane Vesicles (MVs) of Lactobacillus reuteri DSM 17938
por: Grande, Rossella, et al.
Publicado: (2017)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma
por: Smith, Michael P., et al.
Publicado: (2013)

Identification and characterization of the α-CA in the outer membrane vesicles produced by Helicobacter pylori
por: Ronci, Maurizio, et al.
Publicado: (2019)

eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors
por: Hijazi, Maruan, et al.
Publicado: (2022)

A novel combined targeted therapy with bromodomain antagonist and MEK inhibitor in anaplastic thyroid cancer
por: Nucera, Carmelo
Publicado: (2019)

Helicobacter pylori ATCC 43629/NCTC 11639 Outer Membrane Vesicles (OMVs) from Biofilm and Planktonic Phase Associated with Extracellular DNA (eDNA)
por: Grande, Rossella, et al.
Publicado: (2015)

MEK and the inhibitors: from bench to bedside
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Current Development Status of MEK Inhibitors
por: Cheng, Ying, et al.
Publicado: (2017)

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
por: Sweetlove, Melanie, et al.
Publicado: (2015)

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
por: Ramanathan, Ramesh K., et al.
Publicado: (2020)

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
por: Lee, Cha Len, et al.
Publicado: (2023)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
por: Garutti, Mattia, et al.
Publicado: (2022)

Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2
por: Yoshida, Takayuki, et al.
Publicado: (2012)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2014)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2015)

Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs
por: Wei, Bih-Rong, et al.
Publicado: (2022)

Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037
por: Haagensen, Emma J., et al.
Publicado: (2016)

Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
por: Ramanathan, Ramesh K., et al.
Publicado: (2020)

ATRT-16. THE PI3K INHIBITOR PAXALISIB COMBINES SYNERGISTICALLY WITH THE MEK INHIBITOR MIRDAMETINIB TO TARGET ATYPICAL TERATOID/RHABDOID TUMORS
por: Malebranche, Kristen, et al.
Publicado: (2023)

Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
por: Tran, Khanh B., et al.
Publicado: (2021)

DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties
por: Goulielmaki, Maria, et al.
Publicado: (2019)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

MUTYH: Not just polyposis
por: Curia, Maria Cristina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bnjlts4jojlgtc1bfq07f5us7j